Shares of Alnylam Pharmaceuticals plunged Thursday after the biopharmaceutical company stopped development of its drug to treat hereditary conditions that can lead to nerve and heart damage.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source

























